Top

Published in:

Open Access 01-12-2023 | Correction

Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT

Authors: Arnon Nagler, Myriam Labopin, Didier Blaise, Anna Maria Raiola, Lucia Lopez Corral, Stefania Bramanti, Simona Sica, Mi Kwon, Yener Koc, Jiri Pavlu, Alexander Kulagin, Alessandro Busca, Arancha Bermúdez Rodríguez, Péter Reményi, Christoph Schmid, Eolia Brissot, Jaime Sanz, Ali Bazarbachi, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty

Published in: Journal of Hematology & Oncology | Issue 1/2023

Excerpt

Correction : Journal of Hematology & Oncology (2023) 16:58 https://doi.org/10.1186/s13045-023-01450-4 …

Nagler A, et al. Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT. J Hematol Oncol. 2023;16:58. https://doi.org/10.1186/s13045-023-01450-4.CrossRefPubMedPubMedCentral

Title: Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
Authors: Arnon Nagler
Myriam Labopin
Didier Blaise
Anna Maria Raiola
Lucia Lopez Corral
Stefania Bramanti
Simona Sica
Mi Kwon
Yener Koc
Jiri Pavlu
Alexander Kulagin
Alessandro Busca
Arancha Bermúdez Rodríguez
Péter Reményi
Christoph Schmid
Eolia Brissot
Jaime Sanz
Ali Bazarbachi
Sebastian Giebel
Fabio Ciceri
Mohamad Mohty
Publication date: 01-12-2023
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2023
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/s13045-023-01501-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies

Recent advances in targeted strategies for triple-negative breast cancer

Exploiting RIG-I-like receptor pathway for cancer immunotherapy

Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression

Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer